Program
Dronabinol
Also written as “Dronabinol Oral Solution”, “GW-2000-02” and “SP-104”.
Its studies are mostly in Pain · Fasting · Vomiting · Sleep Apnea, Obstructive · Cancer Pain, led by 14 companies.
Drug pageDronabinol: every studyMany companies study it; this page follows only the 20 they lead. All 183 studies, academic ones too, with its approvals and label.Who develops it
Each company that leads studies of it, as its sponsor page counts them.
| Company | Studies it leads | Furthest phase | First study | Next primary completion |
|---|---|---|---|---|
| INSYS Therapeuticsits history only | 30 open or running | phase 1since Oct 5, 2011 | Oct 5, 2011 | none ahead |
| Jazz Pharmaceuticalsits history only | 30 open or running | phase 3since Apr 28, 2008 | Apr 28, 2008 | none ahead |
| Abbottits history only | 20 open or running | phase 3since Mar 21, 2008 | Mar 21, 2008 | none ahead |
| Scilex Pharmaceuticalsits history only | 20 open or running | phase 1since Jul 6, 2021 | Jul 6, 2021 | none ahead |
| Benuvia Therapeuticsits history only | 11 open or running | phase 3since Feb 11, 2026 | Feb 11, 2026 | May 30, 2028phase 3 · NCT07422311 |
| Bionorica Researchits history only | 10 open or running | phase 3since Aug 13, 2009 | Aug 13, 2009 | none ahead |
| CannaXanits history only | 10 open or running | phase 1since Feb 24, 2022 | Feb 24, 2022 | none ahead |
| Daisy Pharma Opioid Ventureits history only | 10 open or running | phase 2since Nov 30, 2018 | Nov 30, 2018 | none ahead |
| FG Brasil LTDAits history only | 10 open or running | phase 3since Mar 8, 2022 | Mar 8, 2022 | none ahead |
| Incannex Healthcareits history only | 11 open or running | phase 2since Jun 3, 2026 | Jun 3, 2026 | Apr 2027phase 2 · NCT07635563 |
| Par Healthits history only | 10 open or running | phase 1since Jun 16, 2011 | Jun 16, 2011 | none ahead |
| SciSparcits history only | 10 open or running | phase 2since Aug 9, 2018 | Aug 9, 2018 | none ahead |
| Sobereyeits history only | 10 open or running | no phasesince Apr 14, 2025 | Apr 14, 2025 | none ahead |
| ZYUS Life Sciences | 10 open or running | phase 2since Jul 25, 2024 | Jul 25, 2024 | none ahead |
Also a collaborator on its studies: KGK Science and FGK Clinical Research.
How these companies relate is not in the registry. A license or acquisition is shown only with a dated source, such as a company release or filing.
History and studies of ZYUS Life Sciences only; the figures above count every company.
History and what’s ahead
From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). Dates ahead are the sponsors’ estimates.
- Jul 25, 2024First study: phase 2 study in Cancer PainFirst studyNCT06533657 · 11 enrolled · Canada
TargetBeta
“Cannabinoid CB1 receptor agonist”ChEMBL 37, by rule
Other programs on CNR1
| Program | Company | Furthest phase | Studies |
|---|---|---|---|
| Cannabidiolrule | Jazz Pharmaceuticals | phase 4 | 68 |
| Rimonabantrule | Sanofi | phase 3 | 39 |
| CRB-913rule | corbus-pharmaceuticals-inc | phase 1 | 1 |
Studies
The one study ZYUS Life Sciences leads. Each opens its study page.
| Study | Phase | Status | Primary completion | Size |
|---|---|---|---|---|
| NCT06533657Cancer Pain · Canada | 2 | Completed | Apr 15, 2026 | 11 |
How it is read
Names in the registry
- “Dronabinol”, 4 entries
- “Dronabinol Oral Solution”, 2 entries
- “GW-2000-02”, 2 entries
- “SP-104”, 2 entries
- “IHL-42X: 2.5 mg dronabinol + 125 mg acetazolamide”, 1 entry
Codes read as this program: GW200002.
Conditions, from the studies’ own filings
- Pain, 3 studies
- Fasting, 2 studies
- Vomiting, 2 studies
- Sleep Apnea, Obstructive, 1 study
- Cancer Pain, 1 study
First seen by our ledger Nov 13, 2026.
What this can’t show
- Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
- Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
- Primary completion dates are the sponsors’ estimates and often move.
- A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.